• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

    6/3/25 9:00:00 AM ET
    $CNTB
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CNTB alert in real time by email

    SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually.

    The presentation details are as follows:

    Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 Asthma

    Abstract Number: 001671

    Presenter: Rekha Chaudhuri, M.D.

    Session Title: Clinical Trials on Airways Diseases

    Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST

    Abstract Title: Improvement in Lung Function with Rademikibart in Eosinophilic Driven, Type 2 Asthma

    Abstract Number: 001678

    Presenter: Rekha Chaudhuri, M.D.

    Session Title: Clinical Trials on Airways Diseases

    Date and Time: Friday, June 13th from 3:00 p.m. – 4:30 p.m. BST

    Following the presentations, each presentation will be available on Connect's website under the presentations and publications section.

    About Connect Biopharma and Rademikibart

    Connect Biopharma is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and COPD. Headquartered in San Diego, California, the company is advancing rademikibart, a next-generation, potentially best-in-class anti-interleukin-4-receptor alpha (IL-4Rα) antibody. With an initial focus on acute exacerbations—an area with significant unmet need—rademikibart has the potential to also drive chronic utilization in asthma and COPD amongst the approximately 1 million asthma patients and 1.3 million COPD patients in the U.S. who experience acute exacerbations annually. In a Phase 2 trial for asthma, rademikibart demonstrated strong efficacy and safety data, with clinically meaningful reductions in exacerbations and rapid, statistically significant improvements in forced expiratory volume in one second (FEV1), observed within one week—and in most cases, within 24 hours via home spirometry.

    For more information visit www.connectbiopharm.com.

    Investor Relations Contact:

    Alex Lobo

    Precision AQ

    [email protected]

    (212) 698-8802

    Media Contact:

    Ignacio Guerrero-Ros, Ph.D., or David Schull

    Russo Partners, LLC

    [email protected]

    [email protected]

    (858) 717-2310 or (646) 942-5604



    Primary Logo

    Get the next $CNTB alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CNTB

    DatePrice TargetRatingAnalyst
    3/4/2024$7.00Buy
    H.C. Wainwright
    More analyst ratings

    $CNTB
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited

      SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

      7/1/24 4:16:48 PM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

      SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

      2/27/24 9:00:28 PM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D/A filed by Connect Biopharma Holdings Limited (Amendment)

      SC 13D/A - Connect Biopharma Holdings Ltd (0001835268) (Subject)

      2/27/24 4:19:26 PM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTB
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $CNTB
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Connect Biopharma Announces Two Oral Presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress

      SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced two oral presentations at the European Academy of Allergy and Clinical Immunology (EAACI) 2025 Annual Congress, taking place June 13-16, 2025, in Glasgow, United Kingdom and virtually. The presentation details are as follows: Abstract Title: Reduction in Annualized Exacerbations with Rademikibart in Eosinophilic Driven, Type 2 AsthmaAbstract Number: 001671Presenter: Rekha Chaudhuri, M.D.Sessio

      6/3/25 9:00:00 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma to Present at Two Upcoming Investor Conferences in June

      SAN DIEGO, May 28, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a clinical-stage biopharmaceutical company focused on transforming acute and chronic care of asthma and chronic obstructive pulmonary disease (COPD), today announced that company management will participate in the following upcoming conferences: Noble Capital Markets Virtual Conference Format: Corporate PresentationDate: Wednesday, June 4th, 2025Time: 9:00 a.m. ET Jefferies Healthcare ConferenceFormat: Corporate PresentationDate: Thursday, June 5th, 2025Time: 7:35 a.m. ETWebcast Link: Register Here The live webcast for the Jefferies Healthcare Conference w

      5/28/25 9:00:00 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Presents Data Supporting Development of Rademikibart at the American Thoracic Society (ATS) 2025 International Conference

      – Rademikibart significantly improved airway function, as measured by FEV1, within a day and significantly reduced acute exacerbations in patients with inflammation-mediated chronic asthma strongly supporting ongoing Phase 2 acute exacerbation studies in asthma and COPD which are expected to report topline data in 1H26 – – New preclinical data highlights differentiated structural and molecular dynamics of rademikibart with enhanced interleukin-4 receptor alpha (IL-4Rα) inhibition compared to dupilumab providing a molecular basis for the differentiated efficacy and safety observed with rademikibart presented at this meeting – SAN DIEGO, May 20, 2025 (GLOBE NEWSWIRE) -- Connect Biopharma H

      5/20/25 9:00:21 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • H.C. Wainwright initiated coverage on Connect Biopharma with a new price target

      H.C. Wainwright initiated coverage of Connect Biopharma with a rating of Buy and set a new price target of $7.00

      3/4/24 7:36:11 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTB
    SEC Filings

    See more
    • SEC Form 10-Q filed by Connect Biopharma Holdings Limited

      10-Q - Connect Biopharma Holdings Ltd (0001835268) (Filer)

      5/15/25 9:08:35 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Holdings Limited filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

      5/15/25 9:03:54 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Holdings Limited filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Connect Biopharma Holdings Ltd (0001835268) (Filer)

      5/14/25 9:10:14 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTB
    Financials

    Live finance-specific insights

    See more
    • Connect Biopharma Announces Positive Rademikibart Global Phase 2b Topline Results in Adult Patients with Moderate-to-Severe Persistent Asthma

      The global trial met its primary endpoint showing both doses of rademikibart treatment significantly improved lung function at Week 12The significant improvement in lung function was observed as early as Week 1 and was sustained through Week 24 with both doses of rademikibartSignificant improvement in asthma control occurred early and was sustained through Week 24 for both doses of rademikibartSafety results suggest rademikibart was generally well toleratedA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:

      12/12/23 6:00:00 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma to Announce Top-Line Data from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma on December 12, 2023

      SAN DIEGO, CA and TAICANG, China, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma" or the "Company"), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced that it will present top-line data from the global Phase 2b trial evaluating rademikibart's efficacy and safety in patients with moderate-to-severe asthma on Tuesday, December 12, 2023, prior to market open. Following the announcement, the Company will host a conference call and webcast presentation at 8:30 a.m. ET to d

      12/11/23 4:05:21 PM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

      Clinical response (IGA 0/1 and EASI-75) achieved at Week 16 with rademikibart treatment was maintained through Week 52 with both every two weeks (Q2W) and every four weeks (Q4W) dosing regimens Approximately 90% of patients on Q4W dose maintained both IGA 0/1 and EASI-75 through Week 52 Over 36 weeks of treatment in Stage 2 of the study, the percentage of patients achieving IGA 0/1 and EASI-75 continued to increaseRademikibart continued to be well tolerated over 52 weeks of treatmentA conference call and webcast presentation to discuss the data will be held today at 8:30 a.m. ET, details below SAN DIEGO, CA and TAICANG, China, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings L

      11/21/23 6:00:00 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $CNTB
    Leadership Updates

    Live Leadership Updates

    See more
    • Attovia Therapeutics Appoints Chief Financial Officer

      FREMONT, Calif., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Attovia Therapeutics announced the appointment of Steven Chan as Chief Financial Officer. Mr. Chan brings extensive financial strategy and operational experience and joins Attovia after serving as Chief Financial Officer at Connect Biopharma (NASDAQ:CNTB), a global clinical-stage biopharmaceutical company focused on T cell-driven therapeutics for inflammatory diseases. At Attovia, Mr. Chan will lead the company's finance and operations functions and serve on its Executive Committee, reporting to Tao Fu, Chief Executive Officer. "I am delighted to welcome Steve to Attovia at this critical growth period for the company. He brings over thirt

      10/15/24 7:30:00 AM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Reports First Half 2024 Financial Results and Provides Business Update

      Announced new U.S.-based leadership with the appointment of Barry Quart, Pharm.D. as Chief Executive Officer (CEO) and David Szekeres as PresidentConnect's new management is currently evaluating the future clinical development strategy for rademikibartAs part of Connect's transformation into a U.S.-centric company, the Company will be significantly reducing its presence in ChinaCash and cash equivalents of $110.2 million expected to support planned operations into at least the first half of 2027 SAN DIEGO, CA, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) ("Connect Biopharma," "Connect" or the "Company"), a U.S.-headquartered global clinical-stage bio

      9/5/24 4:05:00 PM ET
      $CNTB
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Connect Biopharma Announces New Leadership and Chair of the Board of Directors

      Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cel

      6/12/24 4:15:00 PM ET
      $CNTB
      $GRI
      Biotechnology: Pharmaceutical Preparations
      Health Care